Can’t spell Novartis without VART: Drug study retracted for conflict of interest, data issues

A major scandal in Japan over the Novartis hypertension drug valsartan has resulted in a retraction from the Journal of Human Hypertension.  Frequent Retraction Watch subject Hiroaki Matsubara resigned his post at Kyoto Prefectural University in 2013, after his work on valsartan was shown to be riddled with data errors and undisclosed conflicts of interest. Also that year, … Continue reading Can’t spell Novartis without VART: Drug study retracted for conflict of interest, data issues

Weekend reads: Novartis fires scientist for faking data; journal accepts F-bomb-laden spam paper

The week at Retraction Watch began with a case of a South Korean engineer who had to retract ten studies at once. Here’s what was happening elsewhere, along with an update on a story we covered a few days ago:

Retraction appears for faked study of Novartis anti-cancer compound

A paper by a former postdoc at MD Anderson Cancer Center who “admitted to knowingly and intentionally falsifying” a figure has been retracted. In August, the Office of Research Integrity announced that it had sanctioned Jun Fu for faking data in a study of the results of a mouse study of NVP-HSP990, a Novartis compound designed … Continue reading Retraction appears for faked study of Novartis anti-cancer compound

MD Anderson postdoc faked results of Novartis anti-cancer compound study

A former postdoc at MD Anderson Cancer Center faked the results of a mouse study of a Novartis compound designed to fight brain tumors, according to the Office of Research Integrity (ORI). Jun Fu “admitted to knowingly and intentionally falsifying Figure 8a” in “Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor–Initiating … Continue reading MD Anderson postdoc faked results of Novartis anti-cancer compound study

Novartis Diovan scandal claims two more papers

A complicated story involving Novartis’s valsartan (Diovan) has led to the retraction of two more papers, one cascading from the other. Last September, The Lancet retracted the Jikei Heart Study after a slew of retractions of related work prompted an investigation of valsartan research. That investigation found evidence of data manipulation and the failure of … Continue reading Novartis Diovan scandal claims two more papers

Imperial clears Jatinder Ahluwalia of misconduct, blames “protracted negotiation” with Novartis for delay

Imperial College London has found that a former graduate student there — who had been found guilty of misconduct in two other institutions — did not commit fraud while at Imperial. As first reported in the Times Higher Education today:

Cryptic “legal issues” lead to retraction of paper about potential Novartis alcohol abuse drug

Readers of this blog by now know that if there’s one thing that really gets us going, it’s obfuscation. So it shouldn’t be surprising that the following retraction notice from the journal Psychopharmacology, made us particularly batty: This paper has been retracted by the author because of legal issues. The notice refers to  “Selective activation … Continue reading Cryptic “legal issues” lead to retraction of paper about potential Novartis alcohol abuse drug

Weekend reads: Meet journals’ research integrity czars; Duke set to settle big grant fraud case; what a cannabis stock’s collapse can teach investors

Before we present this week’s Weekend Reads, a question: Do you enjoy our weekly roundup? If so, we could really use your help. Would you consider a tax-deductible donation to support Weekend Reads, and our daily work? Thanks in advance. The week at Retraction Watch featured some big numbers: 26 retractions for an engineer in Italy, … Continue reading Weekend reads: Meet journals’ research integrity czars; Duke set to settle big grant fraud case; what a cannabis stock’s collapse can teach investors

An author was accused of faking peer reviews. Turns out he also falsified two images.

In 2015, the journal Cureus published two neurosurgery papers from the same corresponding author, one month apart. Soon after, the journal uncovered “potential irregularities” with two reviews during a routine editorial audit, editor John R. Adler Jr. told Retraction Watch:

How often do scientists who commit misconduct do it again?

When someone has to retract a paper for misconduct, what are the odds they will do it again? And how can we use that information to stop repeat offenders? Those are the questions that  Toshio Kuroki of the Japan Society for the Promotion of Science and Akira Ukawa of RIKEN set out to tackle in … Continue reading How often do scientists who commit misconduct do it again?